TCGA-A2-A25E-01A-11R-A169-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 107
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- PROTEIN_SECRETION+0.520
- MYC_TARGETS_V1+0.470
- G2M_CHECKPOINT+0.440
- MTORC1_SIGNALING+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.350
- ANDROGEN_RESPONSE+0.230
- PEROXISOME+0.220
- MYC_TARGETS_V2+0.210
- OXIDATIVE_PHOSPHORYLATION+0.210
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.330
- INTERFERON_ALPHA_RESPONSE-0.320
- COAGULATION-0.300
- INFLAMMATORY_RESPONSE-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- MYOGENESIS-0.270
- IL6_JAK_STAT3_SIGNALING-0.260
- APICAL_JUNCTION-0.250
- KRAS_SIGNALING_DN-0.250
- WNT_BETA_CATENIN_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.922 |
| 2 | R125 | — | — | 0.910 |
| 3 | R143 | — | — | 0.889 |
| 4 | SJEPD030833_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.888 |
| 5 | SRR1797288 | — | cohortSC | 0.887 |
| 6 | TCGA-HQ-A2OE-01A-11R-A206-07 | — | — | 0.884 |
| 7 | DRR168570 | — | — | 0.883 |
| 8 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.881 |
| 9 | R414 | — | — | 0.880 |
| 10 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.520 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |